Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter Including Lead Clinical Asset, Jotrol Into A Phase 2A Clinical Trial In Parkinson's Disease

Strategic expansion into longevity market creates near-term commercial opportunity alongside continued clinical advancement of JOTROL™

JOTROL™ development programs remain tariff-exempt; consumer longevity line on track with negligible cost exposure

Jupiter, Florida, April 08, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced the release of its first shareholder letter as a publicly traded company. The letter from Chairman and CEO Christer Rosén outlines the Company's 2025 strategic roadmap, including key clinical and commercial milestones designed to create long-term value and establish near-term revenue.

Dear Fellow Shareholders,

It is a distinct pleasure to share our first annual letter to shareholders, following our successful debut on the Nasdaq Capital Market in December 2024 under the symbol JUNS. That significant milestone marked more than just an entry into the public markets — it signaled the beginning of a new era for Jupiter Neurosciences, defined by increased visibility, enhanced resources, and a bold vision for advancing transformative therapies in neuroscience and longevity.

Building Momentum

With our Nasdaq listing in place, we are now focused on advancing our lead clinical asset, JOTROL™, into a Phase 2a clinical trial in Parkinson's disease, expanding our presence in Asia, and launching a new consumer-facing longevity initiative. Becoming a publicly traded company has amplified awareness of our mission — to pioneer treatments that target the underlying causes of neuroinflammation and mitochondria in both rare and widespread neurological disorders. By entering the rapidly growing Longevity and Healthspan market, we are leveraging years of preclinical and clinical development with JOTROL™ to establish a scientifically grounded, near-term revenue-generating business alongside our therapeutic pipeline.

JOTROL™: Unlocking Resveratrol's Untapped Potential

At the core of our pipeline is JOTROL™, an enhanced resveratrol formulation developed in partnership with Aquanova AG. Leveraging proprietary micellar technology, JOTROL™ resolves long-standing bioavailability and gastrointestinal tolerability issues that have hindered therapeutic resveratrol applications for decades. Our Phase 1 study demonstrated more than nine-fold improved bioavailability versus standard resveratrol, and this data now serves as the regulatory foundation across all upcoming clinical trials.

With its ability to cross the blood-brain barrier and modulate key inflammatory pathways such as NLRP3, JOTROL™ is uniquely positioned as a novel therapeutic platform for neurodegenerative diseases, including Parkinson's disease (JNS115) and Mild Cognitive Impairment/Early Alzheimer's (JNS108). The additional benefit of JOTROL™ increasing mitochondrial structure and function is a compounding mechanism that is core to our therapeutic strategy, with treatment benefit in neurodegenerative disease and cancer. Our upcoming Parkinson's trial, in collaboration with Zina Biopharmaceuticals and Catalent, is on track to begin dosing in Q3 2025.